14.21

7.93% -1.225

Intellia Therapeutics Inc (NTLA)

Overview News Price History Option Chain Financials Discussions Forecast

Intellia Therapeutics Inc stock is traded at $14.21, with a volume of 6.16M. It is down -7.93% in the last 24 hours and up +16.52% over the past month. Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Previous Close:

$15.44

Open:

$15.44

24h Volume:

6.16M

Relative Volume:

0.95

Market Cap:

$1.99B

Revenue:

$67.67M

Net Income/Loss:

$-412.69M

P/E Ratio:

-3.7148

EPS:

-3.8266

Net Cash Flow:

$-395.87M

1W Performance:

-19.05%

1M Performance:

+16.52%

6M Performance:

+36.95%

1Y Performance:

+16.90%

1-Day Range:

$14.10

$15.44

1-Week Range:

$14.10

$18.11

52-Week Range:

$7.95

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Name

Intellia Therapeutics Inc

Sector

Healthcare (1096)

Industry

Biotechnology (616)

Phone

857-285-6200

Address

40 ERIE STREET, CAMBRIDGE, MA

Employee

377

Twitter

@intelliatweets

Next Earnings Date

2026-08-06

Latest SEC Filings

NTLA's Discussions on Twitter

Compare NTLA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
NTLA Intellia Therapeutics Inc	14.21	1.99B	67.67M	-412.69M	-395.87M	-3.8266
VRTX Vertex Pharmaceuticals Inc	485.39	123.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	664.52	69.67B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	877.62	54.58B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	298.76	39.89B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	186.88	39.73B	742.00K	-1.37B	-1.07B	-7.0731

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-02-26	Upgrade	William Blair	Mkt Perform → Outperform
Nov-12-25	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-11-25	Downgrade	Evercore ISI	Outperform → In-line
Nov-07-25	Downgrade	JP Morgan	Neutral → Underweight
Oct-28-25	Downgrade	Bernstein	Outperform → Mkt Perform
Oct-28-25	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Oct-27-25	Downgrade	Guggenheim	Buy → Neutral
Oct-27-25	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-25	Upgrade	Citizens JMP	Mkt Perform → Mkt Outperform
Apr-21-25	Upgrade	Wolfe Research	Peer Perform → Outperform
Mar-05-25	Initiated	H.C. Wainwright	Buy
Feb-28-25	Downgrade	Goldman	Neutral → Sell
Feb-28-25	Downgrade	JP Morgan	Overweight → Neutral
Jan-27-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Feb-23-24	Downgrade	Goldman	Buy → Neutral
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Apr-13-23	Initiated	Canaccord Genuity	Buy
Mar-21-23	Initiated	Bernstein	Outperform
Mar-14-23	Upgrade	BMO Capital Markets	Market Perform → Outperform
Feb-01-23	Initiated	Cantor Fitzgerald	Overweight
Jan-24-23	Upgrade	Citigroup	Sell → Neutral
Jan-19-23	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Oct-11-22	Initiated	Morgan Stanley	Overweight
Sep-21-22	Initiated	JP Morgan	Overweight
Sep-01-22	Initiated	Citigroup	Sell
Jun-17-22	Initiated	BMO Capital Markets	Market Perform
Jun-16-22	Initiated	BofA Securities	Buy
Apr-28-22	Initiated	Credit Suisse	Outperform
Feb-18-22	Initiated	William Blair	Outperform
Feb-07-22	Upgrade	Oppenheimer	Perform → Outperform
Jan-31-22	Initiated	Cowen	Outperform
Jan-07-22	Initiated	Piper Sandler	Overweight
Oct-05-21	Initiated	Guggenheim	Buy
Sep-24-21	Initiated	Stifel	Buy
Jun-28-21	Reiterated	H.C. Wainwright	Buy
Jun-11-21	Initiated	H.C. Wainwright	Buy
May-07-21	Upgrade	ROTH Capital	Neutral → Buy
May-04-21	Initiated	RBC Capital Mkts	Outperform
Mar-04-21	Initiated	JMP Securities	Mkt Outperform
Dec-22-20	Downgrade	Robert W. Baird	Outperform → Neutral
Oct-27-20	Initiated	Truist	Buy
Oct-14-20	Initiated	Wells Fargo	Overweight
Sep-18-20	Initiated	Goldman	Buy
Feb-28-20	Upgrade	Oppenheimer	Perform → Outperform
Feb-14-20	Downgrade	Wedbush	Outperform → Neutral
Nov-01-19	Upgrade	Raymond James	Mkt Perform → Outperform
Jul-09-19	Initiated	Robert W. Baird	Outperform
Jun-10-19	Initiated	ROTH Capital	Neutral
May-03-19	Upgrade	Wedbush	Neutral → Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Nov-02-18	Downgrade	Wedbush	Outperform → Neutral
Oct-29-18	Initiated	Credit Suisse	Neutral
Sep-21-18	Initiated	Raymond James	Mkt Perform
May-15-18	Upgrade	Chardan Capital Markets	Neutral → Buy
Mar-08-18	Initiated	JMP Securities	Mkt Outperform
Nov-01-17	Reiterated	Jefferies	Buy
Jun-22-17	Resumed	Jefferies	Buy
Mar-28-17	Initiated	Chardan Capital Markets	Buy
Aug-05-16	Upgrade	Jefferies	Hold → Buy

View All

Intellia Therapeutics Inc Stock (NTLA) Latest News

Jul 11, 2026

Intellia Therapeutics (NTLA) Is Down 12.1% After Positive Phase 3 Lonvo-z Data And 2027 Launch PlansWhat's Changed - Sahm

Jul 11, 2026

Jul 10, 2026

More NTLA, Less RKLB: Cathie Wood’s Latest ARK Trades Explained - Stocktwits

Jul 10, 2026

symbol__ Stock Quote Price and Forecast - CNN

Jul 10, 2026

Intellia Therapeutics (NTLA) Could Be 37% Below Fair Value On Gene Editing Hopes - Sahm

Jul 10, 2026

NTLA Maintained by Wedbush -- Price Target Raised to $17.00 - GuruFocus

Jul 10, 2026

Intellia Therapeutics (NTLA) BofA Securities 2025 Healthcare Conference Summary - Quartr

Jul 10, 2026

NTLA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Jul 10, 2026

NTLA Stock Surges 35% Overnight: Retail Mood Peaks Ahead Of First-Ever Phase 3 Readout For Gene-Editing Therapy - Stocktwits

Jul 10, 2026

Jul 09, 2026